Nuvation Bio Inc Ordinary Shares - Class A NUVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
-
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
-
Nuvation Bio to Participate in Upcoming Investor Conferences
-
Nuvation Bio Granted FDA Fast-Track Designation for Glioma Treatment
-
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
-
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Trading Information
- Previous Close Price
- $4.51
- Day Range
- $4.36–4.59
- 52-Week Range
- $3.92–9.75
- Bid/Ask
- $3.67 / $5.48
- Shares Outstanding
- 351.12M
- Market Cap
- $1.60B
- Volume/Avg
- 44 / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 305
- Website
- https://www.nuvationbio.com
Valuation
|
Metric
|
NUVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.27 |
Price/Sales | 9.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NUVB
|
|---|---|
Quick Ratio | 7.98 |
Current Ratio | 8.37 |
Interest Coverage | −5.41 |
Quick Ratio
NUVB
Profitability
|
Metric
|
NUVB
|
|---|---|
Return on Assets (Normalized) | −16.94% |
Return on Equity (Normalized) | −34.33% |
Return on Invested Capital (Normalized) | −24.93% |
Return on Assets
NUVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Ftt$?$q | LOCK|N>$R< | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?knb<^? | LOCK|Ly^! | $84B | |||
| Moderna Inc
MRNA
| LOCK|>hcxgKg | LOCK|%S | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!j<Zy^ | LOCK|D<m | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!^VhN# | LOCK|x!t | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|C<!V#@ | LOCK|f<pG | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?%&P?L< | LOCK|nyY&y | $29B | |||
| Incyte Corp
INCY
| LOCK|R$LRj^b | LOCK|!CJ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@lGltx | LOCK|x$ | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Cp?G>@% | LOCK|kKV | $14B |
United States